Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas
- PMID: 19723150
- DOI: 10.1111/j.1365-2559.2009.03380.x
Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas
Abstract
Aims: Histological grade is one of the most important prognostic factors in breast carcinomas, but poorly differentiated neoplasms still have quite heterogeneous biological behaviour, since they can be genetically classified as basal-like, HER2+ or even luminal. The aim was to analyse the frequency of oestrogen receptor (ER), progesterone receptor (PR) and HER2 expression profiles among breast carcinomas with <10% tubular formation, and their correlation with classic prognostic factors.
Methods and results: One hundred and thirty-four samples of paraffin-embedded tumours were studied retrospectively. The tumours were classified in to four groups by their ER/PR/HER2 profile: (i) ER+ and/or PR+ but HER2-; (ii) ER+ and/or PR+ and HER2+; (iii) ER- and/or PR- but HER2+; and (iv) ER-, PR- and HER2- (triple-negative). The histological features of triple-negative and HER2+ carcinomas overlap. The only difference was the expression of basal cytokeratins (basal CK), which was more frequent among triple-negative carcinomas. Basal-CK expression defined a more aggressive group of tumours, according to the pathological features, regardless of the immunohistochemical profile.
Conclusions: Group 1 and 2 tumours (ER+ and/or PR+ tumours with or without HER2 expression) were not statistically different, suggesting that poorly differentiated carcinomas with hormone receptors correspond to the luminal B type of tumour. Among poorly differentiated breast carcinomas, the classic profile associated with basal-CK identifies distinct subtypes equivalent to those seen by genetic classification.
Similar articles
-
Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.Rom J Morphol Embryol. 2011;52(3 Suppl):1059-64. Rom J Morphol Embryol. 2011. PMID: 22119825
-
Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.Neoplasma. 2012;59(4):424-32. doi: 10.4149/neo_2012_055. Neoplasma. 2012. PMID: 22489698
-
Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.J BUON. 2013 Jul-Sep;18(3):619-22. J BUON. 2013. PMID: 24065473
-
Breast cancer precursors revisited: molecular features and progression pathways.Histopathology. 2010 Aug;57(2):171-92. doi: 10.1111/j.1365-2559.2010.03568.x. Epub 2010 May 24. Histopathology. 2010. PMID: 20500230 Review.
-
Biological subtypes of breast cancer: current concepts and implications for recurrence patterns.Q J Nucl Med Mol Imaging. 2013 Dec;57(4):312-21. Q J Nucl Med Mol Imaging. 2013. PMID: 24322788 Review.
Cited by
-
Prevalence of molecular subtypes of invasive breast cancer: A retrospective study.Med J Armed Forces India. 2015 Jul;71(3):254-8. doi: 10.1016/j.mjafi.2015.04.006. Epub 2015 Jun 17. Med J Armed Forces India. 2015. PMID: 26288493 Free PMC article.
-
Immunohistochemical study of nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 in invasive breast carcinoma of no special type.Exp Ther Med. 2014 Oct;8(4):1039-1046. doi: 10.3892/etm.2014.1847. Epub 2014 Jul 16. Exp Ther Med. 2014. PMID: 25187794 Free PMC article.
-
Diffusion magnetic resonance imaging in breast cancer characterisation: correlations between the apparent diffusion coefficient and major prognostic factors.Radiol Med. 2015 Mar;120(3):268-76. doi: 10.1007/s11547-014-0442-8. Epub 2014 Aug 6. Radiol Med. 2015. PMID: 25096888
-
Evaluation of prognostic factors in stage IIA breast tumors and their correlation with mortality risk.Clinics (Sao Paulo). 2011;66(4):607-12. doi: 10.1590/s1807-59322011000400014. Clinics (Sao Paulo). 2011. PMID: 21655754 Free PMC article.
-
Melatonin regulates tumor aggressiveness under acidosis condition in breast cancer cell lines.Oncol Lett. 2019 Feb;17(2):1635-1645. doi: 10.3892/ol.2018.9758. Epub 2018 Nov 26. Oncol Lett. 2019. PMID: 30675223 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous